Cabazitaxel Versus Abiraterone or Enzalutamide in Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of the CARD Study Excluding Chemohormonal Therapy for Castrate-naive Disease

Overview

Journal Jpn J Clin Oncol

Publisher Oxford University Press

Specialty Oncology

Date 2021 Mar 19

PMID 33738495

Citations 1

Authors

Hiroyoshi Suzuki

Daniel Castellano

Johann de Bono

Cora N Sternberg

Karim Fizazi

Bertrand Tombal

Christian Wulfing

Meredith C Foster

Ayse Ozatilgan

Christine Geffriaud-Ricouard

Ronald de Wit

Affiliations

Soon will be listed here.

Abstract

Background: In the CARD study (NCT02485691), cabazitaxel significantly improved clinical outcomes versus abiraterone or enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel and the alternative androgen-signalling-targeted inhibitor. However, some patients received docetaxel or the prior alternative androgen-signalling-targeted inhibitor in the metastatic hormone-sensitive (mHSPC) setting. Therefore, the CARD results cannot be directly translated to a Japanese population.

Methods: Patients (N = 255) received cabazitaxel (25 mg/m2 IV Q3W, prednisone, G-CSF) versus abiraterone (1000 mg PO, prednisone) or enzalutamide (160 mg PO) after prior docetaxel and progression ≤12 months on the alternative androgen-signalling-targeted inhibitor. Patients who received combination therapy for mHSPC were excluded (n = 33) as docetaxel is not approved in this setting in Japan.

Results: A total of 222 patients (median age 70 years) were included in this subanalysis. Median number of cycles was higher for cabazitaxel versus androgen-signalling-targeted inhibitors (7 versus 4). Clinical outcomes favoured cabazitaxel over abiraterone or enzalutamide including, radiographic progression-free survival (rPFS; median 8.2 versus 3.4 months; P < 0.0001), overall survival (OS; 13.9 versus 11.8 months; P = 0.0102), PFS (4.4 versus 2.7 months; P < 0.0001), confirmed prostate-specific antigen response (37.0 versus 14.4%; P = 0.0006) and objective tumour response (38.9 versus 11.4%; P = 0.0036). For cabazitaxel versus androgen-signalling-targeted inhibitor, grade ≥ 3 adverse events occurred in 55% versus 44% of patients, with adverse events leading to death on study in 2.7% versus 5.7%.

Conclusions: Cabazitaxel significantly improved outcomes including rPFS and OS versus abiraterone or enzalutamide and are reflective of the Japanese patient population. Cabazitaxel should be considered the preferred treatment option over abiraterone or enzalutamide in this setting.

Citing Articles

Lutetium-177 PSMA radioligand therapy in taxan-naive first- and second-line metastatic castration resistant prostate cancer after first-line ARPI therapy.

Wenzel M, Hoeh B, Siech C, Koll F, Humke C, Groener D Eur J Nucl Med Mol Imaging. 2025; .

PMID: 39804375 DOI: 10.1007/s00259-025-07076-7.

The Efficacy of Cabazitaxel in Treating Prostate Cancer: A Systematic Review and Meta-Analysis.

Hashim H, Khan M, Shah S, Al-Ghuraibawi M, Sulaiman F, Nasrallah J Am J Mens Health. 2024; 18(5):15579883241285162.

PMID: 39367721 PMC: 11459482. DOI: 10.1177/15579883241285162.

References

de Morree E, Bottcher R, van Soest R, Aghai A, de Ridder C, Gibson A . Loss of SLCO1B3 drives taxane resistance in prostate cancer. Br J Cancer. 2016; 115(6):674-81. PMC: 5023781. DOI: 10.1038/bjc.2016.251. View

van Soest R, van Royen M, de Morree E, Moll J, Teubel W, Wiemer E . Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer. Eur J Cancer. 2013; 49(18):3821-30. DOI: 10.1016/j.ejca.2013.09.026. View

Kosaka T, Uemura H, Sumitomo M, Harada K, Sugimoto M, Hayashi N . Impact of pegfilgrastim as primary prophylaxis for metastatic castration-resistant prostate cancer patients undergoing cabazitaxel treatment: an open-label study in Japan. Jpn J Clin Oncol. 2019; 49(8):766-771. PMC: 6939836. DOI: 10.1093/jjco/hyz051. View

Kobayashi T, Terada N, Kimura T, Matsubara N, Murakami K, Mori K . Sequential Use of Androgen Receptor Axis-targeted Agents in Chemotherapy-naive Castration-resistant Prostate Cancer: A Multicenter Retrospective Analysis With 3-Year Follow-up. Clin Genitourin Cancer. 2019; 18(1):e46-e54. DOI: 10.1016/j.clgc.2019.09.011. View

Yamamoto T, Ishizuka O, Oike H, Shiozaki M, Haba T, Oguchi T . Safety and efficacy of cabazitaxel in Japanese patients with castration-resistant prostate cancer. Prostate Int. 2020; 8(1):27-33. PMC: 7125373. DOI: 10.1016/j.prnil.2019.10.005. View

Beer T, Armstrong A, Rathkopf D, Loriot Y, Sternberg C, Higano C . Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014; 371(5):424-33. PMC: 4418931. DOI: 10.1056/NEJMoa1405095. View

Heidenreich A, Bracarda S, Mason M, Ozen H, Sengelov L, van Oort I . Safety of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer: results of the European compassionate-use programme. Eur J Cancer. 2014; 50(6):1090-9. DOI: 10.1016/j.ejca.2014.01.006. View

Sweeney C, Chen Y, Carducci M, Liu G, Jarrard D, Eisenberger M . Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med. 2015; 373(8):737-46. PMC: 4562797. DOI: 10.1056/NEJMoa1503747. View

James N, Sydes M, Clarke N, Mason M, Dearnaley D, Spears M . Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016; 387(10024):1163-77. PMC: 4800035. DOI: 10.1016/S0140-6736(15)01037-5. View

10.

Beer T, Hotte S, Saad F, Alekseev B, Matveev V, Flechon A . Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label,.... Lancet Oncol. 2017; 18(11):1532-1542. DOI: 10.1016/S1470-2045(17)30605-8. View

11.

Kakehi Y, Sugimoto M, Taoka R . Evidenced-based clinical practice guideline for prostate cancer (summary: Japanese Urological Association, 2016 edition). Int J Urol. 2017; 24(9):648-666. DOI: 10.1111/iju.13380. View

12.

Delanoy N, Hardy-Bessard A, Efstathiou E, Moulec S, Basso U, Birtle A . Sequencing of Taxanes and New Androgen-targeted Therapies in Metastatic Castration-resistant Prostate Cancer: Results of the International Multicentre Retrospective CATS Database. Eur Urol Oncol. 2019; 1(6):467-475. DOI: 10.1016/j.euo.2018.05.009. View

13.

Ryan C, Smith M, de Bono J, Molina A, Logothetis C, de Souza P . Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2012; 368(2):138-48. PMC: 3683570. DOI: 10.1056/NEJMoa1209096. View

14.

Suzuki H, Shin T, Fukasawa S, Hashine K, Kitani S, Ohtake N . Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: final subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study. Jpn J Clin Oncol. 2020; 50(7):810-820. PMC: 7345218. DOI: 10.1093/jjco/hyaa030. View

15.

de Wit R, Tombal B, Freedland S . Use of Chemotherapy and Androgen Signaling-targeted Inhibitors in Patients with Metastatic Prostate Cancer. Eur Urol. 2020; 79(2):170-172. DOI: 10.1016/j.eururo.2020.10.016. View

16.

Conteduca V, Castro E, Wetterskog D, Scarpi E, Jayaram A, Romero-Laorden N . Plasma AR status and cabazitaxel in heavily treated metastatic castration-resistant prostate cancer. Eur J Cancer. 2019; 116:158-168. DOI: 10.1016/j.ejca.2019.05.007. View

17.

Oh W, Miao R, Vekeman F, Sung J, Cheng W, Gauthier-Loiselle M . Real-world Characteristics and Outcomes of Patients With Metastatic Castration-resistant Prostate Cancer Receiving Chemotherapy Versus Androgen Receptor-targeted Therapy After Failure of First-line Androgen Receptor-targeted Therapy in the Community.... Clin Genitourin Cancer. 2017; . DOI: 10.1016/j.clgc.2017.06.004. View

18.

Attard G, Borre M, Gurney H, Loriot Y, Andresen-Daniil C, Kalleda R . Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment. J Clin Oncol. 2018; 36(25):2639-2646. PMC: 6118405. DOI: 10.1200/JCO.2018.77.9827. View

19.

Khalaf D, Annala M, Taavitsainen S, Finch D, Oja C, Vergidis J . Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial. Lancet Oncol. 2019; 20(12):1730-1739. DOI: 10.1016/S1470-2045(19)30688-6. View

20.

van Soest R, Nieuweboer A, de Morree E, Chitu D, Bergman A, Goey S . The influence of prior novel androgen receptor targeted therapy on the efficacy of cabazitaxel in men with metastatic castration-resistant prostate cancer. Eur J Cancer. 2015; 51(17):2562-9. DOI: 10.1016/j.ejca.2015.07.037. View